key: cord-0745606-bwbo2sjs
authors: Minihan, B.; McAuliffe, E.; Powell, J.; Wong, S.L.; Wilkie, K.; Murphy, C.; Maher, A.; Power, L.; O’Connell, N.H.; Dunne, C.P.
title: Association between Tocilizumab treatment of hyper-inflammatory patients with COVID-19 in a critical care setting and an elevated incidence of hospital acquired bacterial and invasive fungal infections
date: 2022-04-23
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2022.04.007
sha: 11ab1afcb7c81848879af0035fa07fd1d878505a
doc_id: 745606
cord_uid: bwbo2sjs

BACKGROUND: Tocilizumab is an IL-6 inhibitor that reduces mortality and need for invasive mechanical ventilation, while increasing possibility of successful hospital discharge for hyper-inflammatory patients with severe COVID-19. No increase in adverse events or serious infections have been reported previously. AIM: To describe characteristics and outcomes of patients with severe COVID-19 in critical care who received Tocilizumab. To compare mortality and length of hospital stay for patients who received Tocilizumab (n=41) with those who did not (n=33). METHODS: Retrospective review of data related to patients with COVID-19 who received Tocilizumab in a critical care setting from January 1(st) 2021 to December 31(st) 2021. FINDINGS: Amongst COVID-19 survivors, those administered Tocilizumab had longer ICU stays (median length 21 vs 9 days) and hospital stays (45 vs 34 days) compared to patients who had not received Tocilizumab. 30-day mortality (29% vs. 36%; p=0.5196) and 60-day mortality (37% and 42%; p=0.6138) were were not significantly lower in patients administered Tocilizumab. Serious bacterial and fungal infections occurred at greater frequency amongst patients who received Tocilizumab (OR 2.67, 95% CI 1.04, 6.86; p=0.042) and significantly higher than in non-COVID-19 ICU admissions (OR 5.26, 95% CI 3.08, 9.00; P<0.0001). CONCLUSIONS: In this single-centre study, patients in critical care with severe COVID-19 who received Tocilizumab had a greater number of serious bacterial and fungal infections, but this may not have been a direct effect of Tocilizumab treatment.

Tocilizumab is an IL-6 inhibitor that reduces mortality and need for invasive mechanical ventilation, while increasing possibility of successful hospital discharge for hyperinflammatory patients with severe COVID-19. No increase in adverse events or serious infections have been reported previously.

To describe characteristics and outcomes of patients with severe COVID-19 in critical care who received Tocilizumab. To compare mortality and length of hospital stay for patients who received Tocilizumab (n=41) with those who did not (n=33).

Retrospective review of data related to patients with COVID-19 who received Tocilizumab in a critical care setting from January 1 st 2021 to December 31 st 2021.

Amongst COVID-19 survivors, those administered Tocilizumab had longer ICU stays (median length 21 vs 9 days) and hospital stays (45 vs 34 days) compared to patients who had not received Tocilizumab. 30-day mortality (29% vs. 36%; p=0.5196) and 60-day mortality (37% and 42%; p=0.6138) were were not significantly lower in patients administered Tocilizumab. Serious bacterial and fungal infections occurred at greater frequency amongst patients who received Tocilizumab (OR 2.67, 95% CI 1.04, 6.86; p=0.042) and significantly higher than in non-COVID-19 ICU admissions (OR 5.26, 95% CI 3.08, 9.00; P<0.0001).

In this single-centre study, patients in critical care with severe COVID-19 who received Tocilizumab had a greater number of serious bacterial and fungal infections, but this may not have been a direct effect of Tocilizumab treatment.

On February 20 th 2020, COVID-19 was added to the existing list of notifiable diseases in the Republic of Ireland [1] with the first case of the disease diagnosed less than 10 days later on February 29 th 2020 [2] . To date, the epidemiology of COVID- 19 in Ireland has been characterised by five waves of infection with onsets in March 2020, August 2020, November 2020, June 2021 and December 2021 [3] .

The third wave of COVID19 in Ireland began in late November 2020 peaking during the first week of January 2021. In that week alone, 45,726 cases were diagnosed nationally, with County Limerick reporting 2,470 cases (5.4% of the national total), equating to an incidence of 1267.3 per 100,000 population, the 4 th highest incidence of the disease in the country at that time [4] .

In January 2021 the Health Service Executive (HSE) published interim guidance on the use of Tocilizumab in the management of hospitalised patients with severe COVID-19 [5] .

Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor.

Tocilizumab inhibits the binding of IL-6 to membrane and soluble IL-6 receptors blocking IL-6 signalling and thus reducing inflammation [5] . Its use was to be considered, after multidisciplinary team (MDT) discussion, for patients demonstrating an inadequate response to systemic corticosteroids and who either a) required ICU admission with severe pneumonia necessitating organ support or b) were non-ICU patients with COVID Respiratory Scale (CRC) category C1 (on high-flow nasal oxygen) or C2 (on non-invasive ventilation) disease.

Absolute contraindication to administration of Tocilizumab was acute severe infection from sources other than SARS-CoV-2. [5] .

The aim of our study was to describe the characteristics and outcomes of patients with severe COVID-19 who received Tocilizumab in critical care in our institution. Furthermore, we wished to evaluate whether there were any differences in length of stay or mortality between those patients with severe COVID 19 who received Tocilizumab and those who did not.

J o u r n a l P r e -p r o o f [6] [7] [8] .

Patients included in this review were adults (>18 years of age), admitted to critical care in UHL diagnosed with severe or critical COVID-19 who received Tocilizumab between January 1 st and December 31 st 2021. Diagnosis was determined by detection of SARS-CoV-2 RNA by nasopharyngeal swabs using real time Polymerase Chain Reaction (rtPCR).

Guidance was provided on the staff app regarding the process for convening an urgent MDT when Tocilizumab was being considered as a treatment modality. The Pharmacy Department only dispensed Tocilizumab after confirmation of MDT approval.

The primary outcomes of interest were mortality and length of stay for patients with severe COVID-19 in critical care who received Tocilizumab compared to those who were not administered Tocilizumab. Our secondary objective was to describe the characteristics and outcomes of patients with severe COVID-19 in critical care who received Tocilizumab. Prescribing data were retrieved from pharmacy and chart review.

Only patients with severe COVID-19 infection who were in the ICU requiring organ support were included in this study. Before Tocilizumab was administered patients were assessed for evidence of severe sepsis, including measurement of serum procalcitonin (PCT); a PCT level of >2ug/L was a contraindication to administration of Tocilizumab Microbiology culture results were also examined for evidence of infection, and it was recommended that patients underwent hepatitis B and HIV serological testing and Interferon-Gamma Release Assay (IGRA) test. As this was not a randomised controlled trial, membership of the MDT varied over the duration of the study, and there may have been differences in the assessment of eligibility for Tocilizumab treatment, especially when it was an entirely unfamiliar treatment modality.

Demographic data included age, gender and co-morbidities. Times from symptom onset and COVID-19 diagnosis to administration of Tocilizumab, from hospital admission to critical care admission, and from hospital admission to Tocilizumab administration, were calculated.

Time was calculated and time was calculated. Data on ventilation requirements pre-and post-Tocilizumab administration and on concomitant treatments (including remdesivir, dexamethasone, antibiotics and antifungals) were also collected. Laboratory data collected pre-and post-Tocilizumab administration included leucocyte and lymphocyte levels, Creactive protein (CRP), Ferritin, d-dimer and IL-6 levels. Data on vaccination status were not collected as the National Immunisation Programme for COVID-19 was still in its infancy.

Hospital acquired pneumonia (HAP) was defined as pneumonia, occurring 48 hours or more after admission to hospital, that was not incubating on admission [9] . Ventilator associated pneumonia (VAP) was HAP occuring more than 48 hour after endotracheal intubation [9] . In this study, we did not distinguish between HAP and VAP. Pneumonia was defined as the presence of a new lung infiltrate on imaging along with clinical evidence that would support an infectious aetiology such as new fever, purulent sputum, increasing respiratory requirements and a rising white cell count. This was correlated with microbiological findings which included sputum, tracheal aspirate and blood cultures.

Catheter-associated urinary tract infection (CAUTI) was determined by laboratory detection of bacteriuria in conjunction with clinical signs and symptoms suggestive of a urinary tract infection [10] .

Invasive fungal infection was determined to be proven or probable based on the updated consensus definitions of invasive fungal disease from the European Organisation for

Consortium (EORTC/MSGERC); specifically the definitions that arose from the Intensive Care working group [11, 12] . In the case of invasive aspergillosis, in addition to specified host factors, this included mycological evidence of Aspergillus spp, galactomannan antigen index 98% of patients who received Tocilizumab also received dexamethasone and 63% also received remdesivir. Empiric antibiotics and antifungals were prescribed in 100% and 34% of cases, respectively.

Prior to Tocilizumab administration, 27% of patients (n=11) required mechanical ventilation.

Of the non-ventilated group, 20% required high flow nasal oxygen/AIRVO and 80% were maintained on Non-Invasive Ventilation (NIV). Post-Tocilizumab administration, eighteen further patients progressed to mechanical ventilation (71% total) and the remaining twelve patients (29%) did not. All patients had chest imaging consistent with COVID pneumonitis.

Almost all patients (98%) demonstrated an elevated C-reactive protein with a median value of 96mg/L (range 2 to 283mg/L). A CRP value of >75mg/L was observed in 61%. Serum ferritin was elevated in 78% of cases, with a median of 843ng/ml (range 14 to 4745ng/ml).

D-dimer was elevated in the majority of cases (76%) with a median of 1.76ug/ml (range 0.4 to >4ug/ml); however, it was noted to be in the normal range in 24% of cases. 81% of patients were noted to be lymphopenic with a median of 0.53 x 10 9 /L (range 0.21 to 284 x 10 9 /L). IL-6 was elevated in all but one patient prior to Tocilizumab administration, with a median of 36ng/L (range 3 to 3770ng/L). were unprocessed due to technical issues.

33 patients with COVID-19 were admitted to ICU and did not receive Tocilizumab. They were mostly male (58%) with a median age of 63 (range 32 to 81) years. The majority (85%) had at least one co-morbidity, the most common being cardiovascular disease (42%), diabetes mellitus (39%) and respiratory disease (36%). Of this cohort, 21% were obese ( (range 39-77) years. 81% had more than one co-morbidity, and 46% of these patients died.

Of the 33 patients who did not receive Tocilizumab, 13 (39%) developed a bacterial infection on ICU, with 7 (21%) having more than one infection. There were 10 pneumonias, 9 blood stream infections, 4 catheter-associated urinary tract infections and 1 Clostridioides difficile infection. Median time from hospital admission to bacterial infection was 22 days. There was a slight female predominance (54%); median age was 63 (range 29-77) years. All patients had at least one co-morbidity. Similarly, 46% of this patient cohort died subsequently.

Fungal infections were commoner in the Tocilizumab cohort (7 cases) than in the non- Clostridioides difficile 30-day mortality was 29% for the Tocilizumab group and 36% for the non-Tocilizumab group (p=0.5196). 60-day mortalities were 37% and 42%, respectively (P=0.6138).

Tocilizumab is one of a limited number of treatment options available for COVID-19. It is a humanized monoclonal anti-IL6 antibody that is licensed for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and giant cell arteritis [13] [14] . It acts by preventing IL-6 from binding to soluble and cell-associated IL-6 receptors thereby inhibiting IL-6 mediated signalling. Studies have shown that IL6 levels are elevated in patients with COVID-19 [15] and it is postulated that Tocilizumab may be an effective therapy in COVID19 due to its ability to dampen down the cytokine storm that accompanies severe COVID 19 disease [15] .

Studies of Tocilizumab in COVID-19 have given conflicting results, which may reflect lack of standard protocols for its use [16] [17] [18] [19] [20] . Initial trials demonstrated no clear benefit of inhibitors in this study were found to reduce 28-day in hospital mortality as compared to standard of care, and Tocilizumab was found to reduce both ICU length of stay and mortality, the effect being greater in those who also received steroids [27] . Subsequently the RECOVERY trial showed that Tocilizumab, administered together with corticosteroids, reduced the relative risk of death from COVID 19 at day 28 by 14% and the absolute risk of mortality by 4% in an intention to treat analysis [28] . No mortality benefit was seen when [30] .

A systematic review of Tocilizumab in patients with COVID-19 reported no increased risk of infections in patients receiving Tocilizumab [34] . Similarly, a meta-analysis of 10,930

hospitalised patients with COVID-19 from 27 randomised controlled trials found no association between IL6 antagonists (including Tocilizumab) and risk of 28-day infection [35] . This is in contrast to other reviews that have demonstrated mixed results with varying levels of significance with respect to infection risk and the use of Tocilizumab [36] . This is in contrast to our experience of a significant increase in infections in patients receiving Tocilizumab, two of whom died from their secondary infections.

Our study has several limitations, in that it was a small, single-centre retrospective observational study. Certainly, it would seem that the Tocilizumab group may have had more severe illness, which may account for the prolonged ICU stay. In turn this may have increased the risk of ICU-acquired (particularly medical device-related) infections that were not related to the effects of Tocilizumab.

In conclusion, our study shows that, even though large series have not shown an increased 

Press release: Minister for Health signs regulations to make COVID-19 a Notifiable Disease

Press release: Statement from the National Public Health Emergency Team -Saturday

Epidemiology of COVID 19 in Ireland Frequently asked questions

Health Protection Surveillance Centre: Weekly report on the epidemiology of COVID 19

HSE Interim guidance for the use of Tocilizumab in the management of hospitalised patients with severe COVID 19 disease

programme/hse-interim-guidance-for-the-use-of-tocilizumab-in-the-management-ofhospitalised-patients-with-severe-covid-19-disease-v6

Candidaemia in an Irish intensive care unit setting between

Incidence, management and outcomes of the first cfr-mediated linezolid-resistant Staphylococcus epidermidis outbreak in a tertiary referral centre in the Republic of Ireland

An Irish outbreak of New Delhi metallo-β-lactamase (NDM)-1 carbapenemase-producing Enterobacteriaceae: increasing but unrecognized prevalence

Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia

Clinical Practice Guidelines by the Infectious Diseases Society of America and the

HSE Health Protection Surveillance Centre. Guidelines for the Prevention of Catheterassociated Urinary Tract Infection

Revision and update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group

RoActemra (tocilizumab) An overview of RoActemra and why it is authorised in the EU

IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID 19

Interleukin-6 in Covid-19: A systematic review and meta-analysis

What are the main factors affecting the outcome of tocilizumab therapy in COVID 19 induced cytokine release syndrome?

Success rate of Remdesivir, Convalescent Plasma, and Tocilizumba in moderate to severe COVID 19 pneumonia: our experience in a tertiary care centre

Tocilizumab for COVID 19: A systematic review and meta-analysis of randomized controlled trials

Association between tocilizumab treatment and clinical outcomes of COVID 19 patients: a systematic review and metaanalysis

Tocilizumab in critically ill COVID 19 patients: an observational study

Effect of Tocilizumab on clinical outcome at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

for the BACC Bay Tocilizumab Trial Investigators

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

on behalf of the TOCIVID-19 investigators

The single-arm TOCIVID-19 prospective trial

Tocilizumab in hospitalised patients with severe COVID 19 pneumonia

Tocilizumab in patients hospitalised with COVID 19 pneumonia

Interleukin-6 Receptor Antagonists in Critically ill patients with COVID 19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY); a randomised, controlled, open-label, platform trial

Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Regsistry REGATE

Five-year efficacy and safety of Tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate-and biologic-naïve or free of Methotrexate for 6 months: the AMBITION study

Long-term safety and efficacy of Tocilizumab in patients with rheumatoid arthritis: A of exposure

Risk of Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing Tocilizumab containing treatment

Tocilizumab: A review in rheumatoid arthritis

Efficacy and safety of Tocilizumab in COVID 10 patients: a living systematic review and meta-analysis

Rapid Evidence Appraisal for COVID 19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalised for COVID 19: A Meta-analysis

Infection risk with the use of interleukin inhibitors in hospitalised patients with COVID 19: A narrative review

Antimicrobial Pharmacists at University Hospital Limerick, Limerick, Ireland.

We report no conflict of interest.

We report no funding.J o u r n a l P r e -p r o o f